Want to see SE:ERMA full AI Analyst Report?

Enorama Pharma AB (ERMA) Price & Analysis

0 Followers

ERMA Stock Chart & Stats

kr1.91

-kr0.30(-12.50%)

At close: Mar 06 4:00 PM EST

kr1.91

-kr0.30(-12.50%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr3.00

Previous CloseN/A

Volume29.79K

Average Volume (3M)367.57K

Market Cap

kr52.81M

Enterprise Valuekr18.04

Total Cash (Recent Filing)kr2.10M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.55

Next Earnings

Nov 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.81

Shares Outstanding74,588,684

10 Day Avg. Volume114,750

30 Day Avg. Volume367,567

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)-5.66

Price to Sales (P/S)48.45

P/FCF Ratio-2.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Debt BurdenEffectively zero debt reduces interest obligations and near-term refinancing pressure, giving Enorama more flexibility than a highly leveraged biotech or pharmaceutical company. This provides some financial resilience while management pursues product development and commercialization opportunities.

Focused NRT Product StrategyA focused NRT strategy gives Enorama a clearly defined therapeutic and consumer-health role centered on smoking cessation and nicotine dependence treatment. Concentrating resources on a core product area can support coherent development, regulatory execution, and partnership efforts.

Partnership-based Commercialization ModelUsing established pharmaceutical or consumer-health partners could extend commercial reach without requiring Enorama to build a large sales and distribution organization itself. Upfront, milestone, supply, and royalty mechanisms also provide several possible routes to monetize successful products.

Bears Say

Persistent UnprofitabilityPersistent operating and net losses indicate that the current business has not yet established a sustainable earnings base. Continued losses can consume capital, restrict investment capacity, and make future growth dependent on successful commercialization or additional external financing.

Revenue And Margin DeteriorationThe sharp TTM revenue contraction, combined with deeply negative margins, suggests that current sales are insufficient to support the cost base. The reversal from positive gross profit in 2024 to heavy negative gross profit in 2025 and TTM highlights weak operating stability.

Negative Equity And Ongoing Cash BurnNegative equity signals accumulated balance-sheet losses, while consistently negative operating and free cash flow show that the company is not funding operations internally. This combination limits financial flexibility and increases reliance on external funding to continue development.

ERMA FAQ

What was Enorama Pharma AB’s price range in the past 12 months?

Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.00 in the past 12 months.

What is Enorama Pharma AB’s market cap?

Enorama Pharma AB’s market cap is kr52.81M.

When is Enorama Pharma AB’s upcoming earnings report date?

Enorama Pharma AB’s upcoming earnings report date is Nov 18, 2026 which is in 60 days.

How were Enorama Pharma AB’s earnings last quarter?

Enorama Pharma AB released its earnings results on Aug 19, 2026. The company reported -kr0.176 earnings per share for the quarter.

Is Enorama Pharma AB overvalued?

According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enorama Pharma AB pay dividends?

Enorama Pharma AB does not currently pay dividends.

What is Enorama Pharma AB’s EPS estimate?

Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enorama Pharma AB have?

Enorama Pharma AB has 74,588,684 shares outstanding.

What happened to Enorama Pharma AB’s price movement after its last earnings report?

Enorama Pharma AB reported an EPS of -kr0.176 in its last earnings report. Following the earnings report the stock price went down -13.827%.

Which hedge fund is a major shareholder of Enorama Pharma AB?

Currently, no hedge funds are holding shares in SE:ERMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enorama Pharma AB

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.